Search Results

Displaying Results 1-25 of 123 "'HCC'"

Sep 04, 2026, 07:00 ET Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate

metastatic HCC."ACE723 is an investigational GPC3-targeted dual-payload ADC developed through Acepodia's proprietary AD2C platform, which integrates expertise in antibody engineering, medicinal chemistry and tumor biology. GPC3 is a tumor-associated antigen frequently expressed in HCC, providing

More news about: Acepodia, Inc.

Sep 01, 2026, 08:11 ET Penguin Ai Launches Intelligent Medical Coding and Intelligent Revenue Cycle Management Solutions in AWS Marketplace

organizations. Purpose-built with domain-specific reasoning, agentic automation, and transparent auditability, Penguin Ai accelerates prior authorization, HCC coding and risk adjustment, claims adjudication, payment integrity, appeals, and other mission-critical processes. Penguin Ai integrates with leading

More news about: Penguin Ai

Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

NSCLC.Cadonilimab: Cadonilimab continues to advance across multiple indications, including gastric cancer and hepatocellular carcinoma (HCC). Key programs include an international multicenter Phase III study of cadonilimab plus chemotherapy versus nivolumab plus chemotherapy for first-line

More news about: Akeso, Inc.

Aug 23, 2026, 21:00 ET Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

antibody developability. The platform has already contributed to the nomination of ATG-115, a T-cell engager (TCE) for hepatocellular carcinoma (HCC) directed at a novel, AI-identified tumor-associated antigen. AI-enabled combinatorial screening has also surfaced multiple novel target pairs now

More news about: Antengene Corporation Limited

Aug 21, 2026, 05:20 ET Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy

proof-of-concept studies. These cover EP-NEC, NSCLC, SCLC, BTC, ovarian cancer (OC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), malignant melanoma, and other areas with high unmet medical needs.Mechanistically,

More news about: Nanjing Leads Biolabs Co., Ltd.

Aug 20, 2026, 19:10 ET Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

combination immunotherapy approach for HBV-related HCC.On August 12, 2026, subsequent to the reporting period, the first participant was dosed in a clinical study evaluating BRII-5395 in participants with advanced HCC. The study, conducted at the Cancer Hospital of the

More news about: Brii Biosciences Limited

Aug 19, 2026, 08:11 ET Penguin Ai Launches Utilization Management and HCC Risk Adjustment Solutions in AWS Marketplace

human intervention. For risk adjustment, plans capture accurate HCC codes across the HCC V24 and V28 models and 72,000+ ICD-10 codes, with compliance safeguards built in.Customers can now access Penguin Ai's Utilization Management and HCC Risk Adjustment solutions directly within AWS Marketplace. Because

More news about: Penguin Ai

Aug 18, 2026, 20:15 ET CARsgen Therapeutics Announces 2026 Interim Results

NKG2DL for AML, other malignancies and senescence; KJ-C2527 against Claudin18.2 for G/GEJA, etc.; KJ-C2630 against GPC3 for hepatocellular carcinoma (HCC), etc.Development of In Vivo CAR T-Cell ProductsCARsgen is developing a portfolio

More news about: CARsgen Therapeutics

Aug 12, 2026, 08:09 ET Iterion Therapeutics Strengthens Board with Additions of Manuel Aivado, MD, PhD and Bob Smith

results in patients with advanced hepatocellular carcinoma (HCC) harboring Wnt-pathway activating mutations demonstrated tolerability, clinical benefit, and on-target pharmacodynamic activity, highlighting the potential of tegavivint in HCC and other Wnt-driven cancers.About Iterion TherapeuticsIterion

More news about: Iterion Therapeutics

Aug 11, 2026, 09:30 ET Appian and Synechron introduce Open Underwriting Stack for AI-Powered, Connected Underwriting

replacing the systems they already trust. The Open Underwriting Stack was demonstrated at InsurTech Insights New York with Aaron Lamp, CIO of Tokio Marine HCC PRG, sharing how connected operations are reshaping insurance.Insurance carriers are under pressure to

More news about: Appian

Aug 11, 2026, 09:01 ET Datasea Announces FDA Registration and Device Listing for NeuroVibe Acoustic BCI Biofeedback System as a Class II 510(k)-Exempt Biofeedback Medical Device

Drug Administration ("FDA") for its NeuroVibe Biofeedback System, including products NV-02 and NV-03. The products are listed under FDA product code HCC as Class II 510(k)-exempt biofeedback medical devices within the Neurology regulatory area. FDA establishment registration and device listing do not

More news about: Datasea Intelligent Technology Ltd.

Jul 28, 2026, 09:03 ET MidCap Advisors Advises Leading Midwest Psychiatric Care Provider in Its Acquisition by Health Catalyst Capital

Catalyst Capital (HCC) invests in privately held healthcare services and technology businesses that aim to enhance care quality, access, and affordability. HCC leverages relationships with over 250 major healthcare and technology enterprises to identify sustainable investment themes. HCC drives value creation

More news about: MidCap Advisors, LLC.

Jul 23, 2026, 10:10 ET AbelZeta announces publication in Nature journal highlighting clinical findings for an armored autologous GPC3 CAR-T therapy in patients with advanced hepatocellular carcinoma

manageable safety profile and encouraging antitumor activity for C-CAR031/AZD7003 in 36 patients with heavily pretreated advanced hepatocellular carcinoma (HCC) [median four lines of prior treatment].EfficacyTumor regression was observed in 32 / 36 patients, with a median

More news about: AbelZeta Pharma, Inc.

Jul 21, 2026, 10:07 ET Hyundai Invests in STEM Education and Provides 30,000 Meals in Western Massachusetts Through Hyundai Hope Initiative

Hyundai Hope, also donated to the Food Bank of Western Massachusetts and the Thrive Center Food Pantry at Holyoke Community College (HCC) to help address food insecurity and basic needs.

More news about: Hyundai Motor America

Jul 21, 2026, 08:30 ET The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading?

OriCell / Ori-C101Liver cancer (HCC)Phase II

More news about: T-MAXIMUM PHARMACEUTICAL

Jul 20, 2026, 06:00 ET Holyoke Community College and eCampus.com Expand Partnership with Launch of Equitable Access Program

removing barriers to access."Since 2024, our partnership with eCampus has enabled us to provide students an affordable and convenient option," said HCC vice president of administration and finance Narayan Sampath. "The launch of the Cougar Access program in fall 2026 is another big step towards reducing

More news about: eCampus.com

Jul 15, 2026, 06:30 ET GW RhythmX Now Available in the Microsoft Marketplace

recommendations clinicians can act on before the patient leaves the room.Those recommendations can include documentation improvements, care-gap alerts, HCC and coding opportunities, guideline-based treatment options, and formulary-aware medication alternatives, each backed by supporting evidence. Clinicians

More news about: GW RhythmX

Jul 13, 2026, 04:56 ET Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline

More news about: Leads Biolabs

Jul 10, 2026, 04:53 ET Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC

More news about: Nanjing Leads Biolabs Co., Ltd.

Jun 15, 2026, 00:00 ET Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026

observations."Meanwhile, RZ-001 is currently undergoing clinical development for both recurrent glioblastoma and hepatocellular carcinoma (HCC). The HCC program recently achieved a significant milestone by receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA this

More news about: Rznomics

Jun 08, 2026, 05:45 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

BICR-assessed per mRECIST).This triplet regimen represents a new benchmark for systemic-combined locoregional therapy for patients with unresectable HCC (uHCC).Urological Cancers: Dual Breakthroughs in Prostate and Bladder CancersThe FUZUPRO study, led by Professor Dingwei Ye of Fudan

More news about: Hengrui Pharma

Jun 07, 2026, 20:08 ET OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma

University).In a joint statement, the two investigators said: "In our earlier work on late-line advanced HCC, the BEACON study delivered important progress. GPC3 is specifically overexpressed in HCC and represents an ideal therapeutic target, yet GPC3-directed CAR-T approaches have historically been constrained

More news about: Oricell Therapeutics Holdings Limited

Jobiqo Launches the Hellenic Career Center with AHEPA Chapter 528 for the AHEPA Family of Organizations and the Greek American Community

Jun 03, 2026, 08:44 ET Jobiqo Launches the Hellenic Career Center with AHEPA Chapter 528 for the AHEPA Family of Organizations and the Greek American Community

members, including the Daughters of Penelope, Sons of Pericles, and Maids of Athena. Participating chapters that add the AHEPA Hellenic Career Center (HCC) logo and link to their website are enrolled as revenue-share partners for every job posted on their website. Please like and follow the AHEPA Hellenic

More news about: Jobiqo

Jun 01, 2026, 08:09 ET Iterion Therapeutics Reports First Clinical Validation of Tegavivint as a Targeted Therapy for Wnt-Driven Advanced HCC in Oral Presentation at 2026 ASCO Annual Meeting

demonstrated target engagement, clinical tolerability and monotherapy activity in advanced HCC and other Wnt-driven solid tumors.Iterion is advancing a focused clinical strategy anchored by its lead program in HCC, with clinical development underway in additional Wnt-driven cancers, including mCRC and